Citations

Clear

1446 citation(s) found for "Howard, F".

De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases
Begna, Kebede H. , Kittur, Jaya, Yui, Jennifer , Gangat, Naseema , Patnaik, Mrinal M. , Al‐Kali, Aref , Elliott, Michelle A. , Litzow, Mark R. , Hook, C. Christopher , Wolanskyj, Alexandra P. , Howard, Matthew T., Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Hook, Christopher C., Pardanani, Animesh , Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

British Journal of Haematology | August 4, 2021 | Volume: 195 | Issue: 3 | Pages: 413-416

10.1111/bjh.17742 | PMID 34346084 Get It

SummaryInstitutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment‐induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.
Mechanical Thrombectomy of Carotid Terminus Occlusion Using Direct Aspiration Technique—Video Illustration: 2-Dimensional Operative Video
Kasab, Sami Al , Sattur, Mithun G. , Spiotta, Alejandro M , Group, ENRG, Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Ringer, Andrew J. , Rodríguez, Rafael, Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Ogilvy, Christopher S. , Levitt, Michael R , Schirmer, Clemens M , Ogilvy, Christopher S , Porto, Guilherme , Group, ENRG, Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | July 31, 2021 | Volume: 21 | Issue: 5 | Pages: E441-E442

10.1093/ons/opab272 | PMID 34332504 Get It

Abstract Acute carotid terminus occlusion (CTO) is responsible for up to 5% of acute ischemic strokes secondary to emergent large vessel occlusion (ELVO) and up to 20% of acute internal carotid artery (ICA) occlusions. 1 The term “CTO” has also been used to describe occlusions in the supra-clinoid segment or at the bifurcation of the ICA. Compared to other ELVOs, patients with CTO present with higher stroke severity and larger infarct volume, likely to be a result of disruption of direct Circle of Willis collaterals across the anterior communicating artery (AComA) and posterior communicating artery (PComA). 2,3 Similary, CTO is usually associated with worse prognosis compared to other ELVOs in general. With regard to response to treatment, previous studies have reported significantly lower recanalization rates with intravenous alteplase with CTO compared to M1 segment occlusion. With regard to the safety and efficacy of mechanical thrombectomy, prior reports provide conflicting results with some reporting lower successful recanalization rates with CTO compared to M1 occlusion, and others reporting similar results. In our experience, we have found that successful recanalization of CTO can be achieved with a similar approach to M1 occlusions utilizing a direct aspiration first pass technique (ADAPT). 3,4 Herein, we present a case of CTO for which we performed mechanical thrombectomy using ADAPT. This procedure was an emergent standard of care procedure for which a consent was not required and so not obtained.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Auclair, Daniel , Adam, Stacey J. , Agarwal, Amit , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica R. , Connors, Dana E. , Dash, Ajeeta B. , Bacco, Alessandra Di , Ling, Du, Flores‐Montero, Juan , Ghobrial, Irene M. , Gormley, Nicole , Gupta, Ira, Higley, Howard R., Hillengaß, Jens , Kanapuru, Bindu , Kazandjian, Dickran , Kelloff, Gary J. , Kremer, Brandon E. , Lightbody, Elizabeth D. , Lomas, Oliver , Mateos, María‐Victoria , de, Rocío Montes , Mukundan, Lata , Munshi, Nikhil C. , O’Donnell, Elizabeth , Paiva, Bruno , Patel, Reshma, Pugh, Trevor J. , Ramasamy, Karthik , Ray, Jill, Roshal, Mikhail , Ross, Jeremy A. , Sigman, Caroline C. , Thoren, Katie , Trudel, Suzanne , Ulaner, Gary A. , Valente, Nancy, Weiss, Brendan M. , Zamagni, Elena , Kumar, Shaji , Adam, Stacey J , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica , Connors, Dana E , Dash, Ajeeta B , Di Bacco, Alessandra , Flores-Montero, Juan , Gay, Francesca , Hillengass, Jens , Landgren, C Ola , Lomas, Oliver C , Montes de Oca, Rocio , Pugh, Trevor J , Ramasamy, Karthik , Sigman, Caroline C , Thoren, Katie L , Paiva, Bruno , Ghobrial, Irene M , Ulaner, Gary , Gormley, Nicole , Anderson, Kenneth C. , Avet‐Loiseau, Hervé , Facon, Thierry T.F. , Gay, Francesca , Kirsch, Ilan R. , Landgren, Ola , Lonial, Sagar , Órfão, Alberto , Patel, Reshma, Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | July 28, 2021 | Volume: 27 | Issue: 19 | Pages: 5195-5212

10.1158/1078-0432.ccr-21-1059 | PMID 34321279 Get It

AbstractThe development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
QS5: The Effect of Stem Cells and Local Tacrolimus on Neurite Extension
Saffari, Tiam M. , Chan, Katelyn, Saffari, Sara , Chan, Katelyn, Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 19-19

10.1097/01.gox.0000770024.35327.48 Get It

Purpose: Application of mesenchymal stem cells (MSCs) or tacrolimus (FK506), an FDA approved immunosuppressant, to nerve grafts has been a topic of interest to enhance peripheral nerve regeneration. The aim of this study was to investigate the combined effect of MSCs and local delivery of FK506 on nerve regeneration when applied to nerve autografts and decellularized nerve allografts. Methods: A three-dimensional (3D) in vitro compartmented cell culture system, validated by Tajdaran et al (2019), consisted of rat neonatal dorsal root ganglion (DRG) adjacent to rat nerve autograft or decellularized allograft. This model was used to evaluate regenerating neurites from the DRG into the peripheral nerve scaffold. Nerve autografts and decellularized allografts were augmented with (i) dynamic undifferentiated MSC seeding, (ii) local application of FK506 (100 ng/mL) or (iii) both (N=9/group). Local application was ensured by isolating the central system (i.e. DRG side) from the peripheral system (i.e. nerve graft side), where treatment was applied. After 48-hours of incubation, DRG-nerve graft constructs were collected, fixed, sectioned and stained against neurofilament-160 to measure neurite extension. CD90 staining was used to confirm stem cell characterization. Results: All grafts treated with MSCs confirmed CD90 expression. Compared to untreated autografts, neurite extension in autografts treated with FK506 and autografts treated with MSCs and FK506 combined were found superior (P<0.001 and P=0.0001, respectively), and comparable to autografts treated with MSCs (P=0.12). Compared to untreated allografts, allografts treated with FK506, and allografts treated with MSCs and FK506 were found superior (P<0.001 and P=0.0001, respectively), and allografts treated with MSCs were found comparable (P=0.09). All autograft groups were found superior compared to their respective allograft treatment group (P<0.05). Solely allografts receiving combined treatment were found superior to untreated autografts (P<0.05). Conclusion: MSCs or FK506 treatment improved neurite outgrowth and when combined, this resulted in significant synergistic neurite extension in both autografts and allografts in comparable patterns. Schematic overview of 3D compartmented cell culture system for isolated evaluation of treatment with MSCs and local FK506 in vitro. A 3.5 mm autograft or allograft with or without undifferentiated MSC seeding is attached to a DRG. DRG-nerve graft constructs are placed through a silicone isolator in the middle of a 24-wells plate to isolate the DRG from the nerve graft. FK506 containing media was added to the nerve graft side.
QS1: Regret After Gender Affirmation Surgery: A Systematic Review And Meta-Analysis Of Prevalence
Mascaró, Andrés, Corral, Gabriel Del, Langstein, Howard N. , Manrique, Oscar J. , Bustos, Valeria P. , Bustos, Samyd S. , Escandón, Joseph M. , Gaxiola-García, Miguel Ángel , Kushida-Contreras, Beatriz Hatsue

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 42-43

10.1097/01.gox.0000770160.58231.17 Get It

Purpose : There is an unknown percentage of transgender and gender non-confirming individuals who undergo gender affirmation surgeries (GAS) that experiences regret. Regret could lead to physical and mental morbidity, also questioning the appropriateness of these procedures in selected patients. The aim of this study is to evaluate the prevalence of regret in transgender individuals who underwent GAS and evaluate associated factors. Methods : A systematic review was conducted following the PRISMA guidelines. A comprehensive research strategy was performed including the following databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Random-effects meta-analysis of proportions, subgroup analysis, meta-regression, publication bias, and sensitivity analyses were performed. Results: A total of 27 studies, pooling 7,928 transgender patients that underwent any type of GAS were included in this review. The pooled prevalence of regret after GAS was 1% (95% Confidence interval [CI] <1-2%). Overall, 33% underwent transmasculine surgical procedures and 67% transfeminine procedures. The prevalence of regrets among patients undergoing transmasculine and transfeminine surgeries was <1% (IC<1-<1%) and 1% (CI<1-2%), respectively. A total of 77 patients regretted having had GAS. Of them, 28 had minor and 34 had major regrets based on Pfäfflin’s regret classification. The majority of these had “clear regret” based on Kuiper and Cohen Kettenis’ classification. Conclusion: Based on this review, there is an extremely low prevalence of regret in transgender patients after GAS. We believe this study corroborates the improvements made in regard to selection criteria for GAS. However, there is high subjectivity in the assessment of regret and lack of standardized questionnaires, which highlight the importance of developing validated questionnaires in this population.
Factors associated with long‐term outcomes in pediatric refractory status epilepticus
Gaínza‐Lein, Marina , Aguilar, Cristina Barcia , Piantino, Juan , Chapman, Kevin , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Nayak, Anuranjita , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Reece, Latania, Riviello, James J. , Sannagowdara, Kumar , Sands, Tristan T. , Sheehan, Theodore , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Arya, Ravindra , Farias-Moeller, Raquel , Gaillard, William D , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Sheehan, Theodore , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | July 12, 2021 | Volume: 62 | Issue: 9 | Pages: 2190-2204

10.1111/epi.16984 | PMID 34251039 Get It

AbstractObjectiveThis study was undertaken to describe long‐term clinical and developmental outcomes in pediatric refractory status epilepticus (RSE) and identify factors associated with new neurological deficits after RSE.MethodsWe performed retrospective analyses of prospectively collected observational data from June 2011 to March 2020 on pediatric patients with RSE. We analyzed clinical outcomes from at least 30 days after RSE and, in a subanalysis, we assessed developmental outcomes and evaluated risk factors in previously normally developed patients.ResultsFollow‐up data on outcomes were available in 276 patients (56.5% males). The median (interquartile range [IQR]) follow‐up duration was 1.6 (.9–2.7) years. The in‐hospital mortality rate was 4% (16/403 patients), and 15 (5.4%) patients had died after hospital discharge. One hundred sixty‐six (62.9%) patients had subsequent unprovoked seizures, and 44 (16.9%) patients had a repeated RSE episode. Among 116 patients with normal development before RSE, 42 of 107 (39.3%) patients with available data had new neurological deficits (cognitive, behavioral, or motor). Patients with new deficits had longer median (IQR) electroclinical RSE duration than patients without new deficits (10.3 [2.1–134.5] h vs. 4 [1.6–16] h, p = .011, adjusted odds ratio = 1.003, 95% confidence interval = 1.0008–1.0069, p = .027). The proportion of patients with an unfavorable functional outcome (Glasgow Outcome Scale‐Extended score ≥ 4) was 22 of 90 (24.4%), and they were more likely to have received a continuous infusion.SignificanceAbout one third of patients without prior epilepsy developed recurrent unprovoked seizures after the RSE episode. In previously normally developing patients, 39% presented with new deficits during follow‐up, with longer electroclinical RSE duration as a predictor.
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease
Keret, Ophir , Staffaroni, Adam M. , Ringman, John M. , Goh, Sheng‐Yang M., Wolf, Amy , Allen, Isabel Elaine , Salloway, Stephen , Chhatwal, Jasmeer P. , Reyes‐Dumeyer, Dolly , Bateman, Randall J. , Morris, John C. , Joseph‐Mathurin, Nelly , Perrin, Richard J. , Gordon, Brian A. , Xiong, Chengjie , Vöglein, Jonathan , Fougère, Christian la , Martins, Ralph N. , Sohrabi, Hamid R. , Taddei, Kevin , Villemagne, Victor L. , Fulham, Michael , Masters, Colin L. , Saykin, Andrew J. , Graff‐Radford, Neill R. , Weiner, Michael W. , Cash, David M. , Chrem, Patricio, Rabinovici, Gil D. , Rosen, Howard J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Saykin, Andrew J , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Morris, John C , Cash, David M , Rabinovici, Gil D , Cobigo, Yann , Brickman, Adam M. , Benzinger, Tammie L.S. , Ances, Beau M. , Jucker, Mathias , Schofield, Peter R. , Brooks, William S. , Ghetti, Bernardino , Jack, Clifford R. , Allegri, Ricardo , Su, Yi , Miller, Bruce L. , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 5, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12197 | PMID 34258377 Get It

Abstract Introduction Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD‐MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD‐MC and could help predict risk for dementia during trial enrollment. Methods We created a dementia risk score by entering standardized gray‐matter volumes from 231 DIAD‐MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD‐MC followed longitudinally. Results Our risk score separated asymptomatic versus demented DIAD‐MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD‐MC participants for prevention trials.
Abstract TMP24: Duration of Asymptomatic Status and Outcomes Following Endarterectomy and Stenting in the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)
Moore, Wesley S. , Voeks, Jenifer H. , Roubin, Gary S., Clark, Wayne M. , Jones, Michael R. , Brott, Thomas G. , Investigators, for the CREST, Howard, Virginia J. , Investigators, for the CREST

Mayo Clinic

Stroke | July 3, 2021 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.tmp24 Get It

Introduction: Inclusion of asymptomatic patients in randomized trials comparing revascularization to medical therapy has been questioned if they have been previously symptomatic. Hypothesis: Duration of asymptomatic status is not associated with better outcomes following endarterectomy (CEA) or stenting (CAS). Methods: Patients in CREST were classified as asymptomatic if they had not had a TIA or stroke ipsilateral to the study artery within 6 months prior to randomization. We compared those patients who had always been asymptomatic (AA) to those who had been previously symptomatic (PS) ≥ 6 months prior to randomization. Proportional hazards models adjusting for age and treatment were used to assess risk of 30-day stroke or death (S+D), and risk of any 30-day S+D plus ipsilateral stroke at 4 years by asymptomatic status Results: Among the 1056 asymptomatic patients who received the assigned procedure within 30 days of randomization, 977 (93%) were AA and 79 (7%) were PS. There was no difference in the 30-day and 4 year outcomes (Table). Conclusion: In CREST, 93% of the asymptomatic patients were always asymptomatic. Similar outcomes for the previously symptomatic patients (7%) supports the inclusion of such patients in randomized trials comparing CEA and CAS to medical treatment.
Abstract 15: Trends in Performance and Outcomes of Carotid Endarterectomy Among Elderly Medicare Beneficiaries, 2003-2010
Lichtman, Judith H. , Jones, Michael R. , Sheffet, Alice J., Wang, Yun , Leifheit-Limson, Erica C, Lal, Brajesh K. , Brott, Thomas G. , Howard, George

Mayo Clinic

Stroke | July 3, 2021 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.15 Get It

Background: Carotid endarterectomy (CEA) is the leading procedure for carotid stenosis, yet national data on trends in rates and outcomes are limited. We determined CEA rates among Medicare beneficiaries and evaluated mortality and readmission over 8 years. Methods: We used Medicare fee-for-service data to identify beneficiaries aged ≥65y who had their first CEA (ICD-9 38.12) from 2003-2010 and calculated annual rates per 100,000 person-years (PY). We fit mixed models to assess trends in patient-level outcomes, adjusting for demographics, comorbidities, and symptomatic status. We also evaluated hospital-level trends by calculating risk-standardized mortality (RSMR) and readmission (RSRR) rates. A spatial mixed model adjusted for age, sex, and race was fit to calculate county-specific risk-standardized CEA rates in 2003-2004. Results: There were 505,966 unique CEA hospitalizations. The annual number of CEA discharges decreased from 81,604 in 2003 to 47,597 in 2010 (42% decrease), though the patient characteristics remained largely similar. The national CEA rate was 283 per 100,000 PY in 2003, and there was considerable geographic variability (Figure A). This rate decreased each year to a low of 172 per 100,000 PY in 2010. The rate of stroke or death within 30 days decreased from 3.2 to 2.7%, with a significant adjusted annual reduction of 3% (Figure B). Annual reductions in other short- and long-term outcomes were similar, ranging from 2-3%. The median hospital-level 30-day RSMR decreased over time from 0.99 to 0.57%, while the variation between hospitals increased (interquartile range of 0.7-1.67 percentage points). The 30-day RSRR decreased from 11.0 to 10.1%, but there was more homogeneity across hospitals and years. Conclusions: CEA use among Medicare patients decreased dramatically from 2003-2010, while mortality and readmission outcomes improved. The relative importance of biological and sociological mechanisms for these trends merits further study.
Abstract TP129: Revascularization Risk in Symptomatic versus Asymptomatic Patients - Relative versus Absolute Risk: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
Voeks, Jenifer H. , Brown, O. William, Lal, Brajesh K. , Sheffet, Alice J., Brott, Thomas G. , Hye, Robert J. , Meschia, James F. , Howard, Virginia J. , Howard, George

Mayo Clinic

Stroke | July 3, 2021 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.atp129 Get It

Background: Carotid revascularization was addressed by NASCET and ACAS. NASCET showed a 2-year stroke and death of 32.3% in medical patients and a 15.8% incidence in surgical patients (16.5% absolute/51% relative reduction). Similarly, ACAS revealed an 11% 5-year risk in medical patients and 5.1% in surgical patients (5.9% absolute reduction/53% relative reduction). Absolute risk (rather than relative risk) reduction is of prime interest to the patient. However, in these studies, treatment efficacy was assessed on a relative basis, and these procedures were equally efficacious (51% vs. 53% relative risk). The higher event rates in the symptomatic patients resulted in a larger absolute risk reduction in NASCET (16.5% vs. 5.9%). CREST is the only carotid revascularization study to include both symptomatic and asymptomatic patients undergoing CEA or carotid artery stenting (CAS), and we looked at absolute and relative risks associated with both procedures. Methods: Treatment differences in CREST by symptomatic status were reviewed and interaction terms analyzed. Results: Symptomatic periprocedural stroke and death rates were 6% for CAS vs. 3.2% for CEA (2.8% absolute/47% relative difference/p = 0.02), and were 2.5% for CAS vs. 1.4% for CEA (1.2% absolute/53% relative difference/p = 0.15) for asymptomatic. While treatment differences in periprocedural rates were significant for symptomatic but not asymptomatic patients, there was no difference in treatment efficacy as determined by relative risk reduction. Even the most prominent interaction terms were clearly not significant, p > 0.38. Discussion: There is no evidence of a CAS-CEA difference in treatment efficacy by symptomatic status in CREST. There are significant findings in symptomatic patients. This is likely a product of an increased background rate of events in this strata. While symptomatic status can identify a subgroup with an increased background rate, other factors (e.g. age or stenosis) could identify subgroups of asymptomatic patients with high event rates and large absolute treatment differences.